Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Holdings Raised by Meeder Advisory Services Inc.

Key Points

• Meeder Advisory Services Inc. increased its holdings in Vertex Pharmaceuticals by 13.4% in the first quarter, owning 6,360 shares valued at approximately $3.08 million.
• Institutional investors own 90.96% of Vertex's stock, indicating significant institutional interest in the company.
• Vertex Pharmaceuticals reported $4.06 EPS for the last quarter, missing the expected $4.29, with revenue of $2.77 billion, below estimates of $2.85 billion.

Meeder Advisory Services Inc. lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 13.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,360 shares of the pharmaceutical company's stock after buying an additional 753 shares during the period. Meeder Advisory Services Inc.'s holdings in Vertex Pharmaceuticals were worth $3,083,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in VRTX. GAMMA Investing LLC raised its holdings in Vertex Pharmaceuticals by 60,572.3% during the first quarter. GAMMA Investing LLC now owns 2,425,070 shares of the pharmaceutical company's stock worth $1,175,722,000 after purchasing an additional 2,421,073 shares in the last quarter. Capital World Investors increased its holdings in Vertex Pharmaceuticals by 5.7% in the fourth quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company's stock valued at $11,406,667,000 after buying an additional 1,514,993 shares in the last quarter. Capital Research Global Investors increased its holdings in Vertex Pharmaceuticals by 15.8% in the fourth quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company's stock valued at $4,199,713,000 after buying an additional 1,426,746 shares in the last quarter. Edgewood Management LLC increased its holdings in Vertex Pharmaceuticals by 91.2% in the fourth quarter. Edgewood Management LLC now owns 2,956,608 shares of the pharmaceutical company's stock valued at $1,190,626,000 after buying an additional 1,410,238 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in Vertex Pharmaceuticals by 23.3% in the fourth quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company's stock valued at $2,382,407,000 after buying an additional 1,117,214 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

Vertex Pharmaceuticals Stock Up 1.5%

VRTX stock traded up $6.63 during trading on Friday, reaching $463.50. The stock had a trading volume of 926,157 shares, compared to its average volume of 1,514,342. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a current ratio of 2.65, a quick ratio of 2.29 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $119.03 billion, a P/E ratio of -118.35 and a beta of 0.41. The firm has a fifty day moving average price of $455.09 and a 200 day moving average price of $466.12.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.85 billion. During the same quarter in the prior year, the firm earned $4.76 EPS. The business's quarterly revenue was up 2.6% compared to the same quarter last year. On average, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Wall Street Analyst Weigh In

VRTX has been the subject of a number of research analyst reports. JPMorgan Chase & Co. increased their target price on shares of Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an "overweight" rating in a report on Monday, July 14th. Morgan Stanley dropped their target price on shares of Vertex Pharmaceuticals from $464.00 to $460.00 and set an "equal weight" rating for the company in a report on Friday, June 20th. Royal Bank Of Canada set a $420.00 target price on shares of Vertex Pharmaceuticals and gave the company a "sector perform" rating in a report on Tuesday, June 17th. Leerink Partners reaffirmed a "market perform" rating and issued a $503.00 target price (down from $550.00) on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Fourteen equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Vertex Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $512.30.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.